peptide content comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
== Reception == Since she first appeared in Half-Life 2, Alyx Vance has received positive reviews for both her intelligence and her beauty, among other factors. GamesRadar named Alyx "Miss 2004" due to her intelligence, personality, and design. In its 2010 cover feature, Game Informer named Alyx Vance one of 30 most important characters of the 2000s, feeling that she stands apart from female characters who exist for the sake of male characters without putting too much emphasis on her strength and independence. GamesRadar+ staff also considered her one of the best new characters of the decade due to her strong attitude and personality, which they felt was nonstandard for non-playable characters at the time. Entertainment Weekly's Darren Franich considered her one of the best female characters, feeling that she was a vital component to the game due to Gordon being a silent protagonist. In 2013's BioShock Infinite, the player character's female companion Elizabeth was developed by the team to attempt to live up to Alyx Vance in terms of being an AI companion, with developer Ken Levine arguing that AI companions have not been done as well as Alyx.
Other conditions that may produce similar symptoms include irritable bowel syndrome, celiac disease, and inflammatory bowel disease. Lactose intolerance is different from a milk allergy. Management is typically by decreasing the amount of lactose in the diet, taking lactase supplements (the amount of supplements should be based on the amount of lactose consumed), or treating the underlying disease. People are typically able to drink at least one cup of milk without developing symptoms, with greater amounts tolerated if drunk with a meal or throughout the day. Worldwide, around 65% of adults are affected by lactose malabsorption. Other mammals usually lose the ability to digest lactose after weaning. Lactose intolerance is the ancestral state of all humans before the recent evolution of lactase persistence in some populations, which extends lactose tolerance into adulthood. Lactase persistence evolved in several populations independently, probably as an adaptation to the domestication of dairy animals around 10,000 years ago. Today the prevalence of lactose tolerance varies widely between regions and ethnic groups. The ability to digest lactose is most common in people of Northern European descent, and to a lesser extent in some parts of Central Asia, West Asia, and Africa. Lactose intolerance is most common among people of East Asian descent (with 90% lactose intolerance), people of Jewish descent, people in African and Arab countries, and among some people of Southern European descent.
=== Since 1994 === A new interim constitution, introduced in 1994 after four years of negotiation, finally introduced all-race democracy and enfranchised men and women of all races on equal terms, the minimum age remaining 18 years. Parliament was reconstituted to consist of a Senate and a National Assembly.
=== Brewing fresh leaves === To prepare mint tea from fresh leaves, the leaves are harvested, washed, and placed in boiling water for a few minutes. While fresh and dried leaves have similar flavors, some studies suggest that tea brewed with fresh leaves produces a fresher, more aromatic experience.
The nasal cavity is highly vascularized, allowing efficient transfer of molecules directly to the nervous system. Compared to other administration routes, nasal drug delivery increases bioavailability and reduces systemic exposure risks. The nasal cavity's slightly acidic environment and enzymes can affect drug degradation, making delivery systems with neutral to acidic pH ideal. The respiratory region, with its large surface area and high vascularization, is the primary site for drug absorption into systemic circulation. Targeting the olfactory region enhances nose-to-brain drug delivery, as particles can travel via the olfactory nerve to the brain. This route offers potential for treating brain diseases and mental health conditions.
Sources: en.wikipedia.org
Beefy meaty peptide, also known as delicious peptide and abbreviated as BMP, is an 8-amino acid long peptide that has been identified as giving a beefy flavour to foods in which it is present. It was isolated from beef soup by Yamasaki and Maekawa in 1978. Ongoing research since its discovery by Yamasaki and Maekawa has provided general support for the presence of its flavor-imparting properties. However, due to its high production cost, the peptide's potential for widespread application in the food industry has yet to be realized, prompting current research efforts to focus on finding a method of mass-production for the peptide.
More opioids are taken than intended The individual is unable to decrease the number of opioids used Large amounts of time are spent trying to obtain opioids, use opioids, or recover from taking them The individual has cravings for opioids Difficulty fulfilling professional duties at work or school Continued use of opioids leading to social and interpersonal consequences Decreased social or recreational activities Using opioids despite being in physically dangerous settings Continued use despite opioids worsening physical or psychological health (i.e. depression, constipation) Tolerance Withdrawal The severity can be classified as mild, moderate, or severe based on the number of criteria present. The tolerance and withdrawal criteria are not considered to be met for individuals taking opioids solely under appropriate medical supervision. Addiction and dependence are components of a substance use disorder; addiction is the more severe form.
== History == Efficacy was evaluated in CADENZA (NCT03386513), a multi-center, open-label, single-arm clinical trial that included adult participants with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (N=33) or relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (N=51), without evidence of active central nervous system disease. Efficacy was based on the rate of complete remission or clinical complete remission. The trial included 116 adult participants with CD123-positive blood or bone marrow cancers, of whom 84 participants had blastic plasmacytoid dendritic cell neoplasm. There were 33 participants who had blastic plasmacytoid dendritic cell neoplasm that was never treated before, and 51 participants had blastic plasmacytoid dendritic cell neoplasm that either came back after previous treatment or did not get better with other treatment(s). The trial occurred at 18 locations in four countries: the United States, Italy, Spain, and France. The study included 73 participants in the United States. The benefits and side effects of pivekimab sunirine were evaluated in one open-label trial in adult participants with CD123-positive blood or bone marrow cancers. The efficacy of pivekimab sunirine was evaluated in 84 participants with blastic plasmacytoid dendritic cell neoplasm who received pivekimab sunirine intravenously (through a vein) once every three weeks until the disease worsened or participants experienced unacceptable side effects.
In 2008, 2K Games confirmed that a PlayStation 3 version of the game was in development by 2K Marin. On July 3, 2008, 2K Games announced a partnership with Digital Extremes and said that the PlayStation 3 version is being developed by 2K Marin, 2K Boston, 2K Australia, and Digital Extremes. Jordan Thomas was the director for the PlayStation 3 version. While there were no graphical improvements to the game over the original Xbox 360 version, the PlayStation 3 version offered the widescreen option called "horizontal plus", introduced via a patch on the 360 version, while cutscene videos were of a much higher resolution than in the DVD version. Additional add-on content was also released exclusively for the PlayStation 3 version. One addition was "Survivor Mode", in which the enemies were made tougher, and Vita-Chambers provided less of a health boost when used, forcing the player to be more creative in approaching foes and to rely more on the less-used plasmids in the game. BioShock also supports Trophies and PlayStation Home. A demo version was released on the PlayStation Store on October 2, 2008. The game was released for PlayStation 3 on October 17, 2008, internationally and on October 21 in North America. An update for the PlayStation 3 version was released on November 13, 2008, to fix some graphical problems and occasions where users experienced a hang and were forced to reset the console. This update also incorporated the "Challenge Rooms" and "New Game Plus" features.
== Enrollment == From 2006 to 2019 the number of African-American students remained constant, but the numbers of other racial groups, including Hispanic/Latine and non-Hispanic white students increased. In 2006 the student count was 6,700, including 60 Hispanic/Latine students, in 2019 it was up to 7,700, including 260 Hispanic/Latine students, and in 2024 it was up to 9,808, including 476 Hispanic/Latine students. As of Fall of 2025, there were 11,559 students, being 9,554 undergraduates and 2,005 graduate students enrolled at Morgan, and 45% were non-Maryland residents. The largest sources of enrollment outside of Maryland were New York, New Jersey, and Pennsylvania. Almost 10% of the student population was international, including many from countries like Jamaica, Dominican Republic, Nigeria, and Saudi Arabia. As of Fall 2026, the new record number of enrollment is 12,477 students. The university’s enrollment growth is due not only to the growing interest in HBCUs in general, but also to the institution's dedicated recruiting efforts.
Sources: en.wikipedia.org
== Chemistry == LAAM, or levomethadyl acetate, is the levo isomer of acetylmethadol, or α-methadyl acetate. The dextro isomer, d-alphacetylmethadol (d-α-acetylmethadol), is more potent but shorter acting. The levo isomer is also less toxic with an LD50 in mice of 110 mg/kg s.c. and 172.8 mg/kg orally as opposed to LD50s of 61 mg/kg s.c. and 118.3 mg/kg orally for dl-α-methadyl acetate. It has a melting point of 215 °C and a molecular weight of 353.50. β-methadyl acetate also exists, but is more toxic and less active than α-methadyl acetate and has no current medical use.
Berries are a type of simple fleshy fruit that issue from a single ovary. (The ovary itself may be compound, with several carpels.) The botanical term true berry includes grapes, currants, cucumbers, eggplants (aubergines), tomatoes, chili peppers, and bananas, but excludes certain fruits that are called "-berry" by culinary custom or by common usage of the term – such as strawberries and raspberries. Berries may be formed from one or more carpels (i.e., from the simple or compound ovary) from the same, single flower. Seeds typically are embedded in the fleshy interior of the ovary. Examples include:
The pharmaceutical company Rexar reformulated their weight loss drug Obetrol following its mandatory withdrawal from the market in 1973, under the Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act due to the results of the Drug Efficacy Study Implementation (DESI) program (which indicated a lack of efficacy). The new formulation simply replaced the two methamphetamine components with dextroamphetamine and amphetamine components of the same weight (the other two original dextroamphetamine and amphetamine components were preserved), preserved the Obetrol branding, and despite it lacking FDA approval, it still made it onto the market and was marketed and sold by Rexar for many years. In 1994, Richwood Pharmaceuticals acquired Rexar and began promoting Obetrol as a treatment for ADHD (and later narcolepsy as well), now marketed under the brand name of Adderall, a contraction of the phrase "A.D.D. for All" intended to convey that "it was meant to be kind of an inclusive thing" for marketing purposes. The FDA cited the company for numerous significant CGMP violations related to Obetrol discovered during routine inspections following the acquisition (including issuing a formal warning letter for the violations), then later issued a second formal warning letter to Richwood Pharmaceuticals specifically due to violations of "the new drug and misbranding provisions of the FD&C Act".
Biotextiles are specialized materials engineered from natural or synthetic fibers. These textiles are designed to interact with biological systems, offering properties such as biocompatibility, porosity, and mechanical strength or are designed to be environmentally friendly for typical household applications. There are several uses for biotextiles since they are a broad category. The most common uses are for medical or household use. However, this term may also refer to textiles constructed from biological waste products. These biotextiles are not typically used for industrial purposes. The term "biotextiles" derives from the combination of "bio," referring to biology or living organisms, and "textiles," indicating woven or fibrous materials. It encompasses the interdisciplinary field of biomedical textiles, which focuses on the design, fabrication, and application of textile materials in healthcare and biomedical engineering. Biotextiles made from mycelium, vegetable biomass, bacterial cellulose, and recombinant protein based fibers are used as an alternative to synthetic textiles to prevent and reduce the high greenhouse gas emissions, water pollution, and landfill waste from the textile industry. Biotextiles are also used within healthcare and the biomedical engineering field as implantable devices such as surgical sutures, hernia repair fabrics, arterial grafts, artificial skin and parts of artificial hearts.
That December the headquarters of the 4th Ferrying Group of the Army Air Forces Air Transport Command shifted to the airport. The group was tasked with sending new aircraft overseas; pilots departed Memphis for South America and then flew over the South Atlantic Ocean to Africa. Personnel such as mechanics and engineers underwent training at the base and then traveled overseas. Chicago and Southern's repair facilities at the airport were used to repair military planes. Commercial air service continued, though it was limited. The ferrying group's postwar activities included moving planes off deactivated bases. For a period in 1946, Memphis served as headquarters for the Continental Division of the Air Transport Command, which oversaw the 4th Ferrying Group and ran scheduled flights for military personnel throughout the country. The ferrying group ceased operations in March 1947. City officials reached an agreement with the federal government in January 1949 to regain control of the airfield. Five trunk carriers flew to Memphis as of 1947, and two years later, a regional airline named Southern Airways launched operations with multi-stop service to Atlanta. The airport opened the first air-cargo terminal in the country in February 1958. The following year, passenger counts crossed one million. In August 1960, the city received its first scheduled jet flight; Delta Air Lines started using Convair 880s on its Chicago–Memphis–New Orleans route. The United States Supreme Court in Turner v. City of Memphis ordered the desegregation of the airport in 1962.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.